Prepectoral Implants

Treatments for Breast Cancer With a Certain Genetic Mutation: PARP Inhibitors In January 2018, the FDA approved the first treatment for breast cancer with a certain inherited genetic mutation. Called Lynparza (chemical name: olaparib), it is the first PARP inhibitor to treat breast cancer. The PARP (poly ADP-ribose polymerase) enzyme fixes DNA damage in cells, …